SEC Comment Letter for Sunshine Biopharma Inc. (SBFM, SBFMW) (CIK 0001402328) (SBFM) — Feb 7, 2012

Sunshine Biopharma Inc. (SBFM, SBFMW) (CIK 0001402328)
Date: Feb. 7, 2012 · CIK: 0001402328 · Accession: 0000000000-12-006741

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-52898

Date

February 7, 2012

Author

/s/ Wilson K. Lee

Form

UPLOAD

Company

Sunshine Biopharma Inc. (SBFM, SBFMW) (CIK 0001402328)

Letter

February 7, 2012 VIA E-MAIL Mr. Camille Sebaaly Chief Financial Officer Sunshine Biopharma, Inc. 2015 Peel Street, 5 th Floor Montreal, Quebec, Canada H3A 1T8

Re: Sunshine Biopharma, Inc. Item 4.01 Form 8-K Filed on February 3, 2012 File No. 000-52898

Dear Mr. Camille Sebaaly: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not fore close the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/ Wilson K. Lee
Wilson K. Lee
Staff Accountant

Show Raw Text

February 7, 2012
 VIA E-MAIL

Mr. Camille Sebaaly Chief Financial Officer Sunshine Biopharma, Inc. 2015 Peel Street, 5
th Floor
Montreal, Quebec, Canada H3A 1T8

Re: Sunshine Biopharma, Inc.
 Item 4.01 Form 8-K
Filed on February 3, 2012
 File No. 000-52898

Dear Mr. Camille Sebaaly:
 We have completed our review of your f iling.  We remind you that our comments or
changes to disclosure in res ponse to our comments do not fore close the Commission from taking
any action with respect to the company or th e filing and the company may not assert staff
comments as a defense in any proceeding ini tiated by the Commission or any person under the
federal securities laws of the United States.  We urge all pers ons who are responsible for the
accuracy and adequacy of the disclosure in the filing to be certain that the filing include the
information the Securities Exchange Act of 1934 and all applicable rules require.

                                                                     Sincerely,
   /s/ Wilson K. Lee

       Wilson K. Lee
                Staff Accountant

SecProbe.io